๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2025-05-06

A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials (NCT06172374)

DNAI1 Primary Ciliary Dyskinesia: Genetic Testing, Patient Finding and Increasing Disease Awareness Program

๐Ÿ”ต Active, Not Recruiting Interventional Protocol ๐Ÿ“Š Observational Clinical Research Sponsor: ReCode Therapeutics

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disease.

Who can join: Review the eligibility criteria below.

Location: ReCode Therapeutics, Inc. โ€” Menlo Park, California

Age range: 18 Years

๐Ÿงช Interventions in This Study

  • Sano Genetics Testing Kit (GENETIC)

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • ReCode Therapeutics, Inc. โ€” Menlo Park, California

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—